-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GLPA4IToUI7KfDecAo6c6HJ0CDd6eBrVeK2msRsUPdhPShfUUpgOQIPsQ3MCUS0Z S2xxY3xfoT0nJyPu51OI4g== 0000062391-95-000045.txt : 19951212 0000062391-95-000045.hdr.sgml : 19951212 ACCESSION NUMBER: 0000062391-95-000045 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19951211 SROS: NASD GROUP MEMBERS: HOECHST CORPORATION GROUP MEMBERS: HOECHST MARION ROUSSEL INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL GENESYS INC CENTRAL INDEX KEY: 0000865231 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943061375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-43085 FILM NUMBER: 95600663 BUSINESS ADDRESS: STREET 1: 322 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 4153589600 MAIL ADDRESS: STREET 1: 322 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 9300 WARD PKWY STREET 2: P O BOX 8480 CITY: KANSAS CITY STATE: MO ZIP: 64114 BUSINESS PHONE: 8169664000 MAIL ADDRESS: STREET 1: PO BOX 8480 CITY: KANSAS CITY STATE: MO ZIP: 64114 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13D/A 1 HMRI/HOECHST AMEND. 1 TO CELL GENESYS 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment #1 Under the Securities Exchange Act of 1934 CELL GENESYS, INC. ---------------------------- (Name of Issuer) Common Stock par value $.001 per share - --------------------------------------------------------------------------- (Title of Class of Securities) 150921 10 4 ----------------- (CUSIP Number) William K. Hoskins, Esq. Harry R. Benz General Counsel Hoechst Corporation Hoechst Marion Roussel, Inc. Route 202-206 9300 Ward Parkway P.O. Box 2500 Kansas City, Missouri 64114 Somerville, NJ 08876-1258 (816) 966-4000 (517) 636-1000 - --------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 27, 1995 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(4)(i)(A) or (B), check the following box. [ ] Check the following box if a fee is being paid with this statement [ ]. Page 1 of 6 There is no Exhibit Index 2 CUSIP No. 150921 10 4 ___________________________________________________________________________ 1) Name of Reporting Person and its Hoechst Marion Roussel, Inc. I.R.S. Identification Number 44-0565557 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ X ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Source of Funds WC ___________________________________________________________________________ 5) Check Box if Disclosure of Legal [ ] Proceedings is Required Pursuant to Items 2(d) or 2(e) ___________________________________________________________________________ 6) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 7) Sole Voting Power 2,750,000* Number of ____________________________________________________________ Shares Beneficially 8) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 9) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 10) Shared Dispositive Power 0 ___________________________________________________________________________ 11) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person ___________________________________________________________________________ 12) Check Box If the Aggregate Amount [ ] in Row (11) Excludes Certain Shares ___________________________________________________________________________ 13) Percent of Class Represented 16.5% by Amount in Row (11) ___________________________________________________________________________ 14) Type of Reporting Person CO ___________________________________________________________________________ * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 3 CUSIP No. 150921 10 4 ___________________________________________________________________________ 1) Name of Reporting Person and its Hoechst Corporation I.R.S. Identification Number 22-1862783 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Source of Funds Not applicable ___________________________________________________________________________ 5) Check Box if Disclosure of Legal [ ] Proceedings is Required Pursuant to Items 2(d) or 2(e) ___________________________________________________________________________ 6) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 7) Sole Voting Power 2,750,000* Number of ____________________________________________________________ Shares Beneficially 8) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 9) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 10) Shared Dispositive Power 0 ___________________________________________________________________________ 11) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person ___________________________________________________________________________ 12) Check Box If the Aggregate Amount [ ] in Row (11) Excludes Certain Shares ___________________________________________________________________________ 13) Percent of Class Represented 16.5% by Amount in Row (11) ___________________________________________________________________________ 14) Type of Reporting Person CO ___________________________________________________________________________ * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 4 This Amendment to the Statement on Schedule 13D (the "Schedule 13D") with respect to the Common Stock of Cell Genesys, Inc. (the "Issuer"), of Hoechst Marion Roussel, Inc., a Delaware corporation ("HMRI"), and Hoechst Corporation, a Delaware corporation ("HCorp"), is filed to report the purchase of 2,000,000 shares of Common Stock of the Issuer (the "Shares") and the issuance to HMRI of a warrant (the "Warrant") to purchase up to an additional 750,000 shares of Common Stock (the "Warrant Shares") for $13.00 per share. Except as set forth in this Amendment No. 1, the information set forth in the Schedule 13D remains unchanged. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. - ------- -------------------------------------------------- Item 3 of this Schedule 13D is amended to read as follows: On November 27, 1995, upon the expiration of the Waiting Period under the Hart-Scott-Rodino Antitrust Improvements Act (the "HSR Waiting Period"), for an aggregate price of $20,000,000, HMRI purchased from the Issuer 2,000,000 shares of Common Stock of the Issuer (the "Shares") and a warrant (the "Warrant") to purchase up to an additional 750,000 shares of Common Stock (the "Warrant Shares") for $13.00 per share was issued. The source of funds for the purchase price of $20,000,000 was the working capital of HMRI. None of the funds were borrowed or otherwise obtained for the purpose of acquiring the Shares. The source of funds for the purchase price of $9,750,000 for the Warrant Shares is expected to be the working capital of HMRI and none of such funds are expected to be borrowed or otherwise obtained for the purpose of acquiring the Warrant Shares. ITEM 4. PURPOSE OF TRANSACTION. - ------- ----------------------- Item 4 of this Schedule 13D is amended by adding the following paragraph: The HRS Waiting Period expired and the transactions described herein were consummated on November 27, 1995. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. - ------- ------------------------------------- Paragraph (a) of Item 5 of this Schedule 13D is amended to read as follows. (a) HMRI beneficially owns 2,000,000 Shares of the Issuer's Common Stock representing approximately 12.6% (and 750,000 Warrant Shares together representing approximately 16.5%) of the Issuer's Common Stock outstanding at September 30, 1995 on a fully-diluted basis. The Warrant was issued to HMRI concurrently with the Shares, and HMRI has the right to acquire the Warrant Shares upon payment of the warrant exercise price. Except as may be set forth in any subsequent amendment to the Schedule, neither Hoechst AG nor HCorp, nor any executive officer or director of Hoechst AG, HMRI, or HCorp, beneficially owns any of the Shares or any other shares of Common Stock other than through their beneficial ownership, if any, of stock of Hoechst AG, HCorp, or HMRI. HMRI is a wholly-owned subsidiary of HCorp, which is a wholly-owned subsidiary of Hoechst AG. HCorp disclaims beneficial ownership of securities owned directly by HMRI. 5 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HOECHST MARION ROUSSEL, INC. Date: December 11, 1995 By: /s/ Rebecca R. Tilden Rebecca R. Tilden Vice President, Assistant General Counsel, and Assistant Secretary 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HOECHST CORPORATION Date: December 11, 1995 By: /s/ Harry R. Benz Harry R. Benz Senior Vice President-Finance and Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----